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Abstract A chimeric protein, consisting of streptavidin fused to
a cyclic decapeptide with potent inhibitory activity for matrix
metalloproteinases (MMP), has been produced in Escherichia
coli and purified. The purified chimera formed a tetramer and
showed full biotin-binding ability. The chimera was also capable
of both binding to MMP-2 and inhibiting its activity. Thus, both
the streptavidin moiety and the decapeptide of the chimera are
fully functional. This bifunctional nature of the chimera should
facilitate the application of the decapeptide since the strept-
avidin moiety can be used as a specific conjugation site for
almost any materials upon biotinylation. ß 2002 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
A cyclic decapeptide with the sequence CTTHWGFTLC
was recently isolated as a selective inhibitor of matrix metal-
loproteinase (MMP)-2 and MMP-9 [1], which play key roles
in tumor migration and invasion [2^5]. This peptide also
showed the potential ability to co-localize with tumor vascu-
lature and suppress the growth of tumors. These character-
istics suggest great potential for the CTTHWGFTLC peptide
to serve as a useful reagent for tumor targeting [1,6]. To test
and realize the application of the CTTHWGFTLC peptide
(and other similar peptide-based targeting reagents) for tumor
targeting, it is essential that the peptide can be conjugated to
or labeled with other molecules without disturbing its struc-
ture and properties. However, an extensive e¡ort is generally
required for conjugation and labeling of such peptides with
each partner molecule. Thus, the number of molecular species
that can actually be tested as partner molecules would be
limited. It would be enormously useful if such conjugation
or labeling of the peptide could be done in a simple, yet
e⁄cient and controlled manner.
In this work, we have fused, recombinantly, the
CTTHWGFTLC peptide to streptavidin. Streptavidin, a tet-
rameric protein produced by Streptomyces avidinii, binds D-
biotin with an extremely high a⁄nity (KdV10314 M) [7,8].
The strength of the biotin binding by streptavidin and the
fact that biotin can easily be incorporated into various bio-
logical materials have made the streptavidin-biotin system one
of the most useful molecular tools in biological and medical
sciences [9^11]. A chimeric protein consisting of the
CTTHWGFTLC peptide and streptavidin, if successfully pro-
duced, should allow speci¢c, tight conjugation of the
CTTHWGFTLC peptide to almost any molecules upon bio-
tinylation by using the streptavidin moiety as the conjugation
site. This should facilitate the development of the application
of the CTTHWGFTLC peptide as a tumor-targeting reagent.
Here we describe the design and production of a chimera,
which consists of the CTTHWGFTLC peptide with strept-
avidin. We show that the resulting chimera is bifunctional
and possesses the abilities to bind to both MMP and biotin,
derived from the CTTHWGFTLC peptide and the strept-
avidin moiety, respectively.
2. Materials and methods
2.1. Construction of an expression vector for an Stv-CTTHWGFTLC
chimera
A double-stranded oligonucleotide (5P-CGTGC ACCAC CCACT
GGGGT TTCAC CCTGT GCT-3P and 5P-GATCA GCACA
GGGTG AAACC CCAGT GGGTG GTGCA CGAGC T-3P), en-
coding the sequence CTTHWGFTLC with a translation termination
codon, was cloned between the SacI and BamHI sites of pTSA-18F,
an expression vector for streptavidin-containing chimeras [12]. The
resulting expression vector, pTSA-CTTHWGFTLC, encodes a chi-
meric protein (Stv-CTTHWGFTLC chimera) consisting of the
CTTHWGFTLC peptide fused to the C-terminus of the core region
of streptavidin with a four-residue linker (sequence, NSSS).
2.2. Expression and puri¢cation of the Stv-CTTHWGFTLC chimera
Expression of the Stv-CTTHWGFTLC chimera was carried out by
using Escherichia coli strain BL21(DE3)(pLysE) [13] carrying pTSA-
CTTHWGFTLC, as described [14,15]. Puri¢cation of the expressed
chimera was carried out by the method described earlier [14^17] with
several modi¢cations. An inclusion body fraction was collected from
cell lysates of BL21(DE3)(pLysE)(pTSA-CTTHWGFTLC), which
had been incubated for 4 h after induction, and dissolved in 7 M
guanidine hydrochloride (GdnWHCl; pH 7.0), 0.5 mM EDTA, 10
mM dithiothreitol (DTT), 10 mM 2-mercaptoethanol (2-ME). The
resulting solution was diluted slowly with 20 volumes of Tris-bu¡ered
saline (TBS) [150 mM NaCl, 20 mM Tris^Cl (pH 7.4)] containing 0.5
mM EDTA and 10 mM 2-ME. After the addition of Na2CO3 to 100
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mM, the suspension was ¢ltered through a 5-Wm Durapore membrane
(Millipore). The ¢ltrate was adjusted to pH 10.5 by the addition of
NaOH and applied to a 2-iminobiotin-agarose column (Sigma) [18],
equilibrated with 150 mM NaCl, 100 mM Na2CO3 (pH 11.0), 0.5 mM
EDTA, 10 mM 2-ME. Unbound proteins were removed, and bound
proteins were eluted with 2 M urea, 50 mM sodium acetate (pH 4.0),
0.5 mM EDTA, 10 mM 2-ME. The eluted protein was dialyzed
against phosphate-bu¡ered saline (PBS) [137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 2 mM KH2PO4 (pH 7.2)] containing 0.5
mM EDTA and 10 mM 2-ME, followed by ¢ltration through a
5-Wm Durapore membrane. The ¢ltrate, containing puri¢ed Stv-
CTTHWGFTLC chimeras, was stored at 375‡C until used. Under
these reducing conditions, the CTTHWGFTLC peptide in the chi-
mera should be in a reduced, linear form.
Mild oxidizing conditions were used to form an intra-molecular
disul¢de bond of the CTTHWGFTLC peptide in the chimera (circu-
larization of the CTTHWGFTLC peptide). Puri¢ed chimeras were
dialyzed against PBS containing 0.02% Tween 20 and 0.1 WM ZnCl2.
The concentration of the chimera during dialysis was adjusted to 10
Wg/ml or lower to minimize the formation of inter-molecular disul¢de
bonds. The dialyzed sample was centrifuged at 10 000Ug for 30 min
at 4‡C, and the supernatant was used in subsequent experiments.
2.3. Biotin-binding assays
The biotin-binding ability of the Stv-CTTHWGFTLC chimera was
determined by a gel ¢ltration method [19] using PD-10 columns
(Amersham Pharmacia) or an ultra¢ltration method [20] using Ultra-
free-MC centrifugal ¢ltration units (Millipore).
2.4. MMP inhibition assays
The ability of the Stv-CTTHWGFTLC chimera to inhibit the ac-
tivity of MMP-2 was analyzed by using L-casein as the substrate. Pro-
MMP-2 (1 Wg; Oncogene Research Products) in 50 mM borate (pH
7.5), 5 mM CaCl2, 10 WM ZnCl2, 20% glycerol, 0.005% Brij 35 was
incubated at 37‡C for 2 h in the presence of 0.5 mM p-aminophenyl-
mercuric acetate (APMA) [21]. The resulting activated MMP-2 (5 ng)
was incubated with the chimera (0^12 ng) at 24‡C for 1 h in 50 mM
NaCl, 50 mM Tris^Cl (pH 7.5), 5 mM CaCl2. Then, L-casein (500 ng;
Sigma) was added to each mixture and incubated at 24‡C for 1 h. The
reaction was terminated by the addition of sodium dodecyl sulfate
(SDS) to 0.2%. Each reaction mixture was analyzed by SDS^PAGE
(polyacrylamide gel electrophoresis) [22], and the degradation of
L-casein was used as a measure of MMP activity.
2.5. MMP-binding assays
The ability of the Stv-CTTHWGFTLC chimera to bind to MMP-2
was analyzed by using the chimera immobilized on biotin-coated mi-
crowell plates. The chimera (0^11 ng) was allowed to bind to biotin-
coated microwells (Pierce Chemical), followed by washing the micro-
wells with PBS. APMA-activated MMP-2 (20 ng) in PBS was added
to each microwell and incubated at 4‡C for 3 h. Unbound MMP-2
was collected by washing the microwells with PBS. Bound MMP-2
was released from the microwells by incubation at 50‡C for 20 min
after the addition of GdnWHCl to 2 M. Each of the bound and un-
bound fractions was blotted onto polyvinylidene £uoride membrane
(Millipore), and MMP-2 on the blots was analyzed by immuno-detec-
tion using a rabbit anti-MMP-2 polyclonal antibody (Sigma) with an
ECL Plus Western Blotting Detection System (Amersham Pharma-
cia).
3. Results and discussion
3.1. Design of an Stv-CTTHWGFTLC chimera
The plasmid pTSA-18F [12] was used as a platform for the
construction of an Stv-CTTHWGFTLC chimera. pTSA-18F
carries a truncated streptavidin gene, encoding a core region
of streptavidin [23], under a bacteriophage T7 promoter, x10
[13]. The coding sequence is followed by a polylinker region,
which facilitates the construction of gene fusions with strept-
avidin. A double-stranded oligonucleotide encoding the se-
quence CTTHWGFTLC was inserted into the polylinker re-
gion of pTSA-18F. The resulting expression vector pTSA-
CTTHWGFTLC encodes a chimeric protein, which consists
of the CTTHWGFTLC peptide fused to the C-terminus of
streptavidin (Stv-CTTHWGFTLC chimera; 14.1 kDa) with
a four-residue linker sequence (NSSS).
Both the N- and C-termini of streptavidin are located on
the surface of the molecule [24,25]. Thus, the CTTHWG-
FTLC peptide, fused to the C-terminus of streptavidin, should
be located on the surface of the streptavidin molecule, max-
imizing the accessibility to MMPs. The highly hydrophilic,
£exible four-residue linker, NSSS, between the CTTHWG-
FTLC peptide and streptavidin might also help to expose
the peptide to solvent. The chimera is likely to form a tet-
ramer due to the natural tetrameric structure of streptavidin
[7,8]. Thus, each chimera molecule, consisting of four sub-
units, would have four CTTHWGFTLC sequences present
on the surface.
Two structural characteristics of streptavidin may facilitate
the circularization of the CTTHWGFTLC peptide (intra-sub-
unit disul¢de bonds) in the chimera, which is essential for its
potent inhibitory activities for MMPs [1]. First, natural strept-
avidin has no cysteine. Thus, the streptavidin moiety should
not interfere with the circularization of the CTTHWGFTLC
peptide via disul¢de formation. Second, streptavidin has D2
symmetry with a pseudo-tetrahedral structure [24,25]. The
formation of a disul¢de bond between any two CTTHWG-
FTLC peptides in a single chimera molecule (inter-subunit
Fig. 1. Expression of the Stv-CTTHWGFTLC chimera in E. coli.
Proteins were analyzed by SDS^PAGE and stained with Coomassie
brilliant blue R. The position where the chimera migrates is shown
by arrows. A: Lanes 1, total protein of uninduced cells; 2, total
protein of cells at 4 h after induction. B: Lanes 1, total cell protein
at 4 h after induction; 2, insoluble fraction of cell lysate; 3, soluble
fraction of cell lysate.
Fig. 2. SDS^PAGE of the puri¢ed Stv-CTTHWGFTLC chimera.
A: Puri¢ed chimeras under reducing conditions. Lanes 1, heated for
3 min in boiling water in the presence of SDS, DTT, and 2-ME;
2, in the presence of SDS, DTT, and 2-ME without heat treatment.
B: Puri¢ed chimera after oxidation. Lanes 1, with heat treatment in
the presence of SDS; 2, in the presence of SDS without heat treat-
ment; 3, with heat treatment in the presence of SDS and DTT; 4, in
the presence of SDS and DTT without heat treatment.
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disul¢de bonds) should not be favored due to the relatively
long distance between them.
3.2. Production and puri¢cation of the Stv-CTTHWGFTLC
chimera
The bacteriophage T7 expression system [13] was used to
produce the Stv-CTTHWGFTLC chimera in E. coli. SDS^
PAGE of total cell protein (Fig. 1A) shows that the Stv-
CTTHWGFTLC chimera was expressed e⁄ciently. Expressed
chimeras formed insoluble inclusion bodies in host cells (Fig.
1B). Insoluble fractions were isolated from cell lysates and
dissolved in GdnWHCl under the conditions where any disul-
¢de bonds are reduced to sulfhydryl groups. The resulting
solution was diluted with TBS under reducing conditions to
allow the expressed chimera to refold. Refolded chimeras were
puri¢ed by 2-iminobiotin a⁄nity chromatography [18] under
reducing conditions, where the CTTHWGFTLC peptide
should be in a reduced, linear form. SDS^PAGE of the puri-
¢ed chimera showed a single band at 15 kDa (lane 1, Fig. 2A)
when the chimera was heated in boiling water in the presence
of SDS, under which conditions streptavidin dissociates into
subunits [26]. On SDS^PAGE of the puri¢ed chimera without
heat treatment, under which conditions streptavidin maintains
its tetrameric structure [26], the chimera showed a single band
at 60 kDa (lane 2), indicating that the chimera forms a sub-
unit tetramer, as predicted.
The puri¢ed Stv-CTTHWGFTLC chimera was subjected to
mild oxidizing conditions to circularize the CTTHWGFTLC
peptide. To minimize the formation of inter-molecular disul-
¢de bonds, low protein concentrations (10 Wg/ml or lower)
were used. When higher protein concentrations were used,
signi¢cant amounts of insoluble aggregates were seen, indicat-
ing the formation of extensive inter-molecular disul¢de bonds.
SDS^PAGE of the chimera after mild oxidation shows that
the chimera subunit migrated at 15 kDa, and no subunit
dimer is seen in the absence of reducing agents (lane 1, Fig.
2B). Under the conditions where the tetrameric structure of
streptavidin is maintained, the chimera migrated at 60 kDa,
indicating virtually no multimer formation (lane 2). These
data suggest that the conditions used for the circularization
of the CTTHWGFTLC peptide e¡ectively prevented the for-
mation of inter-molecular disul¢de bonds. The migration of
the oxidized chimera subunit (lane 1) is almost the same as
that under reducing conditions. Thus, the addition of DTT to
the oxidized chimera had little e¡ect on the migration of the
chimera subunit (lane 3). In contrast, the migration of the
tetramer became slightly faster after oxidization (lane 2).
The addition of DTT to the oxidized chimera (lane 4) made
the migration of the tetramer slower than the level seen with
the chimera before oxidation. These results reveal that the
overall structure of the chimera in the presence of SDS be-
came more compact upon oxidation, suggesting that intra-
subunit disul¢de bonds of the CTTHWGFTLC peptide were
formed e⁄ciently under the conditions used.
3.3. Characterization of the Stv-CTTHWGFTLC chimera
The puri¢ed Stv-CTTHWGFTLC chimera was character-
ized for the functionality of each of the two moieties. The
chimera showed a full biotin-binding ability, both before
and after the circularization of the CTTHWGFTLC peptide,
indicating that the fusion of the CTTHWGFTLC peptide has
little, if any, e¡ect on the biotin-binding ability of the strept-
avidin moiety.
The ability of the Stv-CTTHWGFTLC chimera to inhibit
the activity of MMPs was investigated by using MMP-2. The
chimera with circularized CTTHWGFTLC peptides was
mixed with APMA-activated MMP-2 at various ratios. Then,
L-casein was added to the mixtures, and the degradation of
L-casein was monitored by SDS^PAGE (Fig. 3). When the
chimera was mixed with activated MMP-2 at approximately
10-fold molar excess, caseinolysis was completely inhibited
(lane 5). However, little or no inhibition of caseinolysis was
seen when the chimera was not included in reaction mixtures
or lower molar ratios of the chimera to MMP-2 were used
(lanes 1^4). Natural streptavidin, used in place of the Stv-
CTTHWGFTLC chimera, showed no e¡ect on caseinolysis
by MMP-2 (data not shown). These results suggest that the
CTTHWGFTLC peptide in the chimera retains its inhibitory
activity for MMPs. However, relatively high concentrations of
the chimera were required for complete inhibition of MMP
activity. This is in good agreement with a previous study on
the CTTHWGFTLC peptide [1].
The Stv-CTTHWGFTLC chimera was then examined for
its ability to bind to MMP-2. The chimera with circularized
CTTHWGFTLC peptides was immobilized on biotin-coated
microwells. Then, APMA-activated MMP-2 was allowed to
Fig. 3. Inhibition of MMP-2 activity by the Stv-CTTHWGFTLC
chimera. APMA-activated MMP-2 was pre-incubated with the oxi-
dized chimera. L-Casein was added as the substrate to each mixture,
which was analyzed by SDS^PAGE for the degradation of L-casein.
The amounts of the chimera used in lanes 1^5 are: 0, 0.1, 0.5, 2.4,
and 12 ng, respectively. Lane 6 shows a control sample, in which
no MMP-2 was included in the mixture. The positions where L-ca-
sein and its degradation product migrate are shown by arrows.
Fig. 4. Binding of MMP-2 to the Stv-CTTHWGFTLC chimera.
APMA-activated MMP-2 was allowed to bind to the oxidized chi-
mera, which had been immobilized on biotin-coated microwells. Un-
bound and bound MMP-2 fractions were blotted on polyvinylidene
£uoride membrane and analyzed by immuno-detection using an
anti-MMP-2 antibody. A: Stv-CTTHWGFTLC chimera. The
amounts of the chimera used in each reaction are: wells 1, 0; 2,
0.11 ng; 3, 1.1 ng; 4, 11 ng. B: Natural streptavidin. The amounts
of natural streptavidin used in each reaction are: wells 1, 0; 2, 0.25
ng; 3, 2.5 ng; 4, 25 ng.
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bind to immobilized chimeras, and MMP-2 in both the bound
and unbound fractions was analyzed. The immobilized chi-
mera was able to capture MMP-2, when 1.1 or 11 ng of the
chimera was used for binding reactions (Fig. 4A). Almost no
binding of MMP-2 was seen when the chimera was not in-
cluded or only 0.11 ng of the chimera was used. The binding
of MMP-2 was not seen when natural streptavidin, in place of
the chimera, was immobilized, independent of the amount
used (Fig. 4B). This suggests that the binding of MMP-2 to
the immobilized chimera is speci¢c and mediated by the
CTTHWGFTLC peptide of the chimera. These results dem-
onstrate that the CTTHWGFTLC peptide of the chimera re-
tains the binding ability for MMP-2. As predicted from the
MMP-2 inhibition assays above, the binding a⁄nity of the
chimera for MMP-2 appears to be relatively low, and high
concentrations of the chimera may be required for e⁄cient
binding to MMP-2.
3.4. Conclusion
We have successfully produced a chimeric protein, consist-
ing of the CTTHWGFTLC peptide with streptavidin, in
which both the CTTHWGFTLC peptide and the streptavidin
moiety are fully functional. The bifunctional nature of the
chimera should facilitate the development of the application
of the CTTHWGFTLC peptide since the streptavidin moiety
allows speci¢c, indirect conjugation of the peptide to almost
any materials upon biotinylation. Additionally, recombinantly
fusing to streptavidin, which serves as a speci¢c, versatile con-
jugation site, could be useful as a general strategy for the
characterization and application of many other peptide-based
targeting reagents. The tetrameric structure of such chimeras
might also enhance the binding a⁄nity of the peptides for
targets expressed in high densities on the cell surface.
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